<DOC>
	<DOCNO>NCT01081795</DOCNO>
	<brief_summary>The purpose study determine recommend dose topiramate participant migraine ( type severe headache occur periodically often associate nausea , vomit , constipation diarrhea ) , verify superiority ( statistically effective ) drug placebo ( inactive substance compare drug test whether drug real effect clinical trial ) , assess therapeutic effect observe study overseas Caucasian clinical study .</brief_summary>
	<brief_title>A Dose-Finding Study Topiramate ( JNS019 ) Participants With Migraine</brief_title>
	<detailed_description>This study multicenter ( 1 site ) , placebo-controlled ( compare placebo ) , randomize ( participant assign study drug chance ) , double-blind ( neither participant physician know assign study drug ) , parallel-group comparison ( comparison group time ) study . The study period consist 4 phase : observation phase , double-blind phase , exit period follow-up period . After double-blind phase , participant transfer continuous treatment study . The observation phase start informed consent consist washout period ( non-treatment period migraine preventive medication : least 2 week ) baseline determination period ( least 4 week ) . The participant complete observation phase meet inclusion criterion randomly assign topiramate 50 milligram ( mg ) group , topiramate 100-mg group placebo group registration . The double-blind phase consist titration period ( dose-escalation , 4 week ) fixed-dose period ( 18 week ) . In titration period , start 1 topiramate 25-mg tablet 1 topiramate 25-mg placebo tablet daily ( 1 tablet evening ) , dose increase 1 tablet every week twice daily ( 2 tablet morning , 2 tablet even ) . After , twice-daily treatment ( 2 tablet morning , 2 tablet even ) continue 7 day Day 22 Day 28 . In fixed-dose period , topiramate 25-mg tablet topiramate 25-mg placebo tablet dose final treatment titration period continue . The participant transfer continuous treatment study completion double-blind phase discontinuation double-blind phase transfer exit period ( 1 week ) .The participant complete exit period transfer follow-up period , follow-up participant 's safety headache symptom migraine period rate conduct 4 week completion investigational treatment . Meanwhile , participant complete double-blind phase discontinue study Week 4 later fixed-dose period double-blind phase due lack efficacy give consent transfer continuous treatment study transfer transfer period ( 3 week ) blind condition .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Participants meet Second Edition International Classification Headache Disorders ( ICHDII ) , 1.1 Migraine without aura 1.2 Migraine aura least 6 month time inform consent Participants average 8 migraine attack per month 3 month inform consent average 14 headache ( migraine nonmigraine ) day Participants whose number migraine attack baseline determination period ( 28 day ) 3 12 accord 24hour rule number headache day ( migraine nonmigraine ) 14 Participants take migraine preventive medication 2 week informed consent , take least 2week washout period baseline determination period take migraine preventive medication Female participant must postmenopausal , surgically sterile , abstinent , take adequate contraceptive measure inform consent continue completion investigational treatment Participants distinguish migraine nonmigraine headache Participants headache describe ICHDII , 1.1 Migraine without aura , 1.2 Migraine aura , 2 . Tension headache 11.5 Sinus headache If participant receive drug therapy prevention migraine , discontinue preventive therapy due insufficient efficacy least three type Participants excessively take medication migraine attack analgesic ( drug use control pain ) medication take need within 3 month inform consent Participants take topiramate ( test drug study ) past</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Topiramate</keyword>
	<keyword>Migraine</keyword>
</DOC>